[One picture, one drug] Janssen Amivantamab was approved for marketing, the world's first bispecific antibody for the treatment of NSCLC

Long press the QR code to receive Amivantamab (Rybrevant®) developed by Janssen Biotechnology, which is a bispecific antibody targeting c-MET/HGFR and EGFR.

The drug was approved by the US FDA on May 21, 2021 for the treatment of non-small cell lung cancer with EGFR mutations [1].

Lung cancer is the most common type of tumor, and it is also a tumor with high mortality worldwide.
About 80-85% of lung cancer patients are non-small cell lung cancer.

2~3% of patients with non-small cell lung cancer have EGFR exon 20 insertion mutations.
This mutation form is the third most common EGFR mutation, which can lead to the rapid proliferation and migration of tumor cells [2].

Amivantamab was approved based on a multi-center, open-label, multi-cohort trial that included 81 NSCLC patients with EGFR exon 20 insertion mutations.

The data showed that the overall remission rate ORR was 40%, the median duration of remission DOR was 11.
1 months, and 63% of patients had remission duration of more than 6 months (NCT02609776) [3].

The details of Amivantamab and the double-antibody drugs targeting c-MET/HGFR and EGFR are shown in the following figure: (click to enlarge to view) You can also click the link below to get the corresponding PDF high-definition version: https://data.
pharmacodia.
com/v3/insight /#/ListPdf?tag=2Reference materials 1.
Drug crossing data https://data.
pharmacodia.
com 2.
https:// -therapy-subset-non-small-cell-lung-cancer3.
https:// APP ``points new game method'' company enjoys the database super value Permission to talk about the top 10 global sales of pharmaceutical dry granulation technology in 2020.
Discussing the ups and downs of 20 years, where is the future of kinase inhibitors? Click "Read the original text" to keep abreast of industry trends